Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial
Background: Quercetin, a natural polyphenol with demonstrated broad-spectrum antiviral, anti-inflammatory, and antioxidant properties, has been proposed as an adjuvant for early-stage coronavirus disease 2019 (COVID-19) infection.Objective: To explore the possible therapeutic effect of quercetin in...
Main Authors: | Francesco Di Pierro, Amjad Khan, Somia Iqtadar, Sami Ullah Mumtaz, Muhammad Nabeel Akbar Chaudhry, Alexander Bertuccioli, Giuseppe Derosa, Pamela Maffioli, Stefano Togni, Antonella Riva, Pietro Allegrini, Martino Recchia, Nicola Zerbinati |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1096853/full |
Similar Items
-
The Human Microbial Metabolism of Quercetin in Different Formulations: An In Vitro Evaluation
by: Giuseppe Di Pede, et al.
Published: (2020-08-01) -
Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial
by: Francesco Di Pierro, et al.
Published: (2023-11-01) -
Development of Olive Oil Containing Phytosomal Nanocomplex for Improving Skin Delivery of Quercetin: Formulation Design Optimization, In Vitro and Ex Vivo Appraisals
by: Omnia M. Hendawy, et al.
Published: (2023-03-01) -
Two-month period of 500 mg lecithin-based delivery form of quercetin daily dietary supplementation counterbalances chronic fatigue symptoms: A double-blind placebo controlled clinical trial
by: Mariangela Rondanelli, et al.
Published: (2023-11-01) -
Clinical Effects of <i>Streptococcus salivarius</i> K12 in Hospitalized COVID-19 Patients: Results of a Preliminary Study
by: Francesco Di Pierro, et al.
Published: (2022-09-01)